Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

@article{Bisceglie1995RibavirinAT,
  title={Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.},
  author={Adrian M Di Bisceglie and Hari S. Conjeevaram and Michael W. Fried and Richard Sallie and Yoon Park and Cihan Yurdaydin and Manorama Swain and David E Kleiner and Kelly Mahaney and Jay H. Hoofnagle},
  journal={Annals of internal medicine},
  year={1995},
  volume={123 12},
  pages={897-903}
}
OBJECTIVE To evaluate ribavirin, an oral antiviral agent, as therapy for chronic hepatitis C. DESIGN Randomized, double-blind, placebo-controlled study. SETTING Clinical Center of the National Institutes of Health, a tertiary referral research hospital. PATIENTS 29 patients with chronic hepatitis C who received oral ribavirin (600 mg twice daily) for 12 months and 29 controls with chronic hepatitis C who received placebo for 12 months. MEASUREMENTS Effects of therapy were evaluated by… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

Similar Papers

Loading similar papers…